Hangzhou Tongee Medical Technology Co., Ltd. is a national high-tech enterprise dedicated to building an innovative platform for interventional gastrointestinal therapies and related medical equipment, disease management and solutions. After years of unremitting efforts, we have successfully developed a number of new medical technologies for metabolic diseases such as obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease. In January 2024, the Gastric Bypass Stent System was approved as an innovative Class III medical device in China and received "Breakthrough Device Designation" from the US FDA in October 2024. As of May 2026, it had completed medical device registration in nine countries and regions: Hong Kong, Indonesia, Thailand, Vietnam, Malaysia, Saudi Arabia, Ecuador, Colombia, and Philippines. In September 2025, the first implantation in Southeast Asia was completed in Indonesia. In addition, we have established multiple technology platforms and ISO13485-certified R&D, quality, manufacturing, and supply chain management system. As of May 2026, we have 200+ patents and patent applications. Tongee is an innovation-driven and doctor- and patient-centered company dedicated to ushering in a new era of interventional treatment for metabolic diseases and creating a better life for patients around the world!